ヒトパピローマウイルスワクチン市場- 世界の産業規模、シェア、動向、機会＆予測、タイプ別、疾患別、流通チャネル別、地域別、競合、2020-2030Fセグメント別

ヒトパピローマウイルス（HPV）ワクチンの世界市場は、2024年に83億5,000万米ドルと評価され、2030年には137億7,000万米ドルに達し、CAGR 8.65%で成長すると予測されています。

同市場は、世界の予防接種とがん予防イニシアチブの要であり、HPV関連疾患に対する意識の高まりと予防接種キャンペーンの拡大によって力強い成長を遂げています。HPV関連疾患の有病率の増加は、ヘルスケア投資の改善やワクチン接種戦略の世界の実施と相まって、引き続き市場の需要を牽引しています。WHOやGAVIのような国際保健機関からの支援は、ワクチンへのアクセスや摂取をさらに加速させています。単回接種ワクチンレジメン、性別にとらわれないワクチン接種プログラム、追跡・管理のためのデジタルヘルス技術などの革新的なアプローチの導入により、世界のワクチン接種率が向上し、HPVによるがんの負担が長期的に軽減されることが期待されます。

市場促進要因

HPV関連疾患の有病率の上昇

主な市場課題

高いワクチンコストと価格設定の制約

主要市場動向

性別を含むワクチン接種プログラムの拡大

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 ヒトパピローマウイルスワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（二価、四価、九価）
  • 疾患別（子宮頸がん、膣がん・外陰がん、肛門がん、口腔咽頭（頭頸部）がん、性器疣贅）
  • 流通チャネル別（病院、薬局、政府系サプライヤー、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米のヒトパピローマウイルスワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のヒトパピローマウイルスワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域のヒトパピローマウイルスワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のヒトパピローマウイルスワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのヒトパピローマウイルスワクチン市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のヒトパピローマウイルスワクチン市場：SWOT分析

第14章 競合情勢

• Merck & Co., Inc.
• GSK plc.
• Serum Institute of India Pvt. Ltd
• Sanofi
• Pfizer Inc.
• Inovio Pharmaceuticals, Inc
• Walvax Biotechnology Co., Ltd
• Bharat Biotech Ltd
• Johnson & Johnson Services, Inc.
• Moderna, Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

The Global Human Papillomavirus (HPV) Vaccine Market was valued at USD 8.35 Billion in 2024 and is projected to reach USD 13.77 Billion by 2030, growing at a CAGR of 8.65%. This market is a cornerstone of global immunization and cancer prevention initiatives, witnessing strong growth propelled by rising awareness of HPV-associated diseases and expanded immunization campaigns. Increased prevalence of HPV-related conditions, coupled with improved healthcare investments and the global implementation of vaccination strategies, continues to drive market demand. Support from international health bodies like WHO and GAVI has further accelerated vaccine accessibility and uptake. The introduction of innovative approaches, such as single-dose vaccine regimens, gender-neutral vaccination programs, and digital health technologies for tracking and administration, is expected to improve global vaccine coverage and reduce the burden of HPV-induced cancers over time.

Key Market Drivers

Rising Prevalence of HPV-Related Diseases

The growing prevalence of HPV-related diseases is a major force driving the expansion of the HPV vaccine market. HPV remains one of the most common sexually transmitted infections worldwide, with current statistics indicating that approximately 10% of women globally are carriers at any given time. This widespread presence results in significant health consequences, including about 620,000 new cancer cases in women and 70,000 in men annually, largely driven by cervical, oropharyngeal, and anal cancers. With cervical cancer alone accounting for nearly 530,000 new diagnoses each year, the burden on public health systems is substantial. The increasing rate of infection has led to greater reliance on vaccination as a preventive measure, particularly in regions with high incidence rates, reinforcing the demand for HPV vaccines across both developed and developing countries.

Key Market Challenges

High Vaccine Cost and Pricing Constraints

The high cost associated with HPV vaccines presents a substantial challenge, particularly in low- and middle-income countries where the disease burden is often highest. Budget limitations within public health systems can restrict large-scale procurement, limiting vaccine access to the broader population. These pricing challenges hinder market penetration and slow down immunization program adoption in resource-constrained areas. Manufacturers and global health agencies are increasingly exploring tiered pricing models and strategic collaborations to improve affordability and expand market reach, yet cost remains a limiting factor for universal vaccine access.

Key Market Trends

Expansion of Gender-Inclusive Vaccination Programs

A notable trend in the HPV vaccine market is the shift toward gender-inclusive vaccination policies. Historically targeted at adolescent girls to prevent cervical cancer, immunization programs are now expanding to include boys and young men in response to growing evidence linking HPV to a broader spectrum of cancers, such as oropharyngeal and anal cancers. This inclusive approach significantly increases the eligible vaccination population and provides a new avenue for manufacturers and healthcare providers to improve coverage rates. Broader demographic targeting enhances the potential for widespread immunity and further supports efforts to reduce the overall incidence of HPV-related diseases globally.

Key Market Players

• Merck & Co., Inc.
• GSK plc.
• Serum Institute of India Pvt. Ltd
• Sanofi
• Pfizer Inc.
• Inovio Pharmaceuticals, Inc
• Walvax Biotechnology Co., Ltd
• Bharat Biotech Ltd
• Johnson & Johnson Services, Inc.
• Moderna, Inc.

Report Scope

In this report, the Global Human Papillomavirus Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human Papillomavirus Vaccine Market, By Type:

• Bivalent
• Quadrivalent
• Nonavalent

Human Papillomavirus Vaccine Market, By Disease:

• Cervical Cancer
• Vaginal and Vulvar Cancers
• Anal Cancer
• Oropharyngeal (Head and Neck) Cancers
• Genital Warts

Human Papillomavirus Vaccine Market, By Distribution Channel:

• Hospitals and Retail Pharmacies
• Government Suppliers
• Others

Human Papillomavirus Vaccine Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human Papillomavirus Vaccine Market.

Available Customizations

Global Human Papillomavirus Vaccine market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Human Papillomavirus Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Bivalent, Quadrivalent, Nonavalent)
  • 5.2.2. By Disease (Cervical Cancer, Vaginal and Vulvar Cancers, Anal Cancer, Oropharyngeal (Head and Neck) Cancers, Genital Warts)
  • 5.2.3. By Distribution Channel (Hospitals and Retail Pharmacies, Government Suppliers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Human Papillomavirus Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Disease
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Human Papillomavirus Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Disease
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. Canada Human Papillomavirus Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Disease
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Mexico Human Papillomavirus Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Disease
      • 6.3.3.2.3. By Distribution Channel

7. Europe Human Papillomavirus Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Disease
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Human Papillomavirus Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Disease
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. United Kingdom Human Papillomavirus Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Disease
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Italy Human Papillomavirus Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Disease
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. France Human Papillomavirus Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Disease
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. Spain Human Papillomavirus Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Disease
      • 7.3.5.2.3. By Distribution Channel

8. Asia-Pacific Human Papillomavirus Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Disease
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Human Papillomavirus Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Disease
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. India Human Papillomavirus Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Disease
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Japan Human Papillomavirus Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Disease
      • 8.3.3.2.3. By Distribution Channel
  • 8.3.4. South Korea Human Papillomavirus Vaccine Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Disease
      • 8.3.4.2.3. By Distribution Channel
  • 8.3.5. Australia Human Papillomavirus Vaccine Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Disease
      • 8.3.5.2.3. By Distribution Channel

9. South America Human Papillomavirus Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Disease
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Human Papillomavirus Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Disease
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Human Papillomavirus Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Disease
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Human Papillomavirus Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Disease
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Human Papillomavirus Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Disease
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Human Papillomavirus Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Disease
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Human Papillomavirus Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Disease
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Human Papillomavirus Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Disease
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Human Papillomavirus Vaccine Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Merck & Co., Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. GSK plc.
• 14.3. Serum Institute of India Pvt. Ltd
• 14.4. Sanofi
• 14.5. Pfizer Inc.
• 14.6. Inovio Pharmaceuticals, Inc
• 14.7. Walvax Biotechnology Co., Ltd
• 14.8. Bharat Biotech Ltd
• 14.9. Johnson & Johnson Services, Inc.
• 14.10.Moderna, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer